← Leaderboards
Thota Ganesh
Emory University
$8,173,561
Attributed
$10,654,529
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.4M · FY2016–25$2.5M$1.9M$1.3M$625K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,654,529 · 7
By mechanism
U01$7,037,844 · 2
UH3$1,327,964 · 1
UG3$1,152,900 · 2
R21$746,525 · 1
R33$389,296 · 1
Top collaborators
- Raymond J Dingledine3 shared
- Tage Honore2 shared
Most similar at Emory University
Same institution · by research overlap
- Larry J Young$28,392,997
- Kerry J. Ressler$45,428,982
- Stephen T. Warren$38,020,626
- Jason R Richardson$15,517,223
- Mark E Wilson$24,274,420
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposPharmaceutical PreparationsFormulationOralBrainEpilepsyReceptorStatus EpilepticusDinoprostonePlasmaDoseInflammationDrug KineticsProstaglandinsPreventMicrogliaMediatingRodentBlood - Brain Barrier AnatomyS DiseaseCyclooxygenase 2Disease ProgressionCognitive DeficitsNeuroinflammation
Grant awards (16)
Development of EP2 Receptor Antagonist to Treat Alzheimer's Disease$1,392,306
U01 · FY2025 · AG · contact PI
Development of EP2 Receptor Antagonist to Treat Alzheimer's Disease$1,737,244
U01 · FY2024 · AG · contact PI
Optimization of EP2 Antagonists for Post-Seizure Cognitive Deficits$648,477
UH3 · FY2024 · NS · contact PI
Optimization of EP2 Antagonists for Post-Seizure Cognitive Deficits$679,487
UH3 · FY2023 · NS · contact PI
Optimization of EP2 Antagonists for Post-Seizure Cognitive Deficits$677,532
UG3 · FY2022 · NS · contact PI
Development of EP2 receptor antagonists for suppression of Alzheimer's neuropathology$712,064
U01 · FY2020 · AG · contact PI
EP2 Antagonist Development for Post-seizure Cognitive Deficits$475,368
UG3 · FY2020 · NS
EP2 antagonists as novel anti-epileptogenic agents$389,296
R33 · FY2020 · NS · contact PI
Development of EP2 receptor antagonists for suppression of Alzheimer's neuropathology$214,285
U01 · FY2020 · AG · contact PI
Development of EP2 receptor antagonists for suppression of Alzheimer's neuropathology$702,664
U01 · FY2019 · AG · contact PI
EP2 antagonists as novel anti-epileptogenic agents$342,807
R21 · FY2019 · NS · contact PI
Development of EP2 receptor antagonists for suppression of Alzheimer's neuropathology$696,509
U01 · FY2018 · AG · contact PI
EP2 antagonists as novel anti-epileptogenic agents$403,718
R21 · FY2018 · NS · contact PI
Development of EP2 receptor antagonists for suppression of Alzheimer's neuropathology$83,038
U01 · FY2018 · AG · contact PI
Development of EP2 receptor antagonists for suppression of Alzheimer's neuropathology$741,585
U01 · FY2017 · AG · contact PI
Development of EP2 receptor antagonists for suppression of Alzheimer's neuropathology$758,149
U01 · FY2016 · AG · contact PI